A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab

A 72-year-old man with a 10-year history of coronary heart disease started evolocumab treatment once a month after developing excess myalgia due to therapy with a 3-hydroxy-methylglutaryl CoA reductase inhibitor. No side effects such as myalgia symptoms had been reported during the first 14 months o...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Ikuo, Takenaka, Yasuhiro, Kin, Yoshitora, Yamazaki, Satoshi, Ikegami, Yuichi, Saito, Daigo, Shimada, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136763/
https://www.ncbi.nlm.nih.gov/pubmed/32274224
http://dx.doi.org/10.1155/2020/3281626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136763/
https://www.ncbi.nlm.nih.gov/pubmed/32274224
http://dx.doi.org/10.1155/2020/3281626

Ejemplares similares